On July 15, 2013, The U.S. Food and Drug Administration issued a press release announcing its decision to allow the marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old.
The complete press release may be found at:
WINAHEAD 